ArticleBMC pregnancy and childbirth2026
Integrated metabolomic and transcriptomic analysis identifies enhanced phosphatidylcholine metabolism in placenta accreta spectrum.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPlacenta accreta spectrum (PAS) is a serious obstetric complication with limited understanding of its molecular basis. This study investigates metabolic and transcriptomic alterations in PAS placentas to uncover potential mechanisms and biomarkers.
methodsPlacental tissues from PAS patients (n = 19) and controls (n = 10) underwent untargeted metabolomics via Liquid chromatography-tandem mass spectrometry (LC-MS/MS). Differential metabolites were analyzed for pathway enrichment. RNA sequencing was performed to identify differentially expressed genes (DEGs), followed by Kyoto Encyclopedia of Genes and Genomes (KEGG) and disease ontology enrichment. Integrated metabolomic-transcriptomic analysis was used to identify key metabolic pathways, and findings were validated in an expanded cohort (22 PAS cases, 50 controls). Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic performance of Lecithin, phosphate cytidylyltransferase 1 beta (PCYT1B), and their combination for predicting PAS.
resultsA total of 203 metabolites were differentially expressed in PAS placentas, with lipid and lipid-like molecules comprising the largest class. Several phosphatidylcholine (PC) species were significantly upregulated, indicating dysregulated glycerophospholipid metabolism. Transcriptome analysis identified 578 DEGs, including upregulation of PCYT1B and endothelial lipase (LIPG), both involved in lipid metabolism. Enrichment analysis revealed activation of glycerolipid and glycosphingolipid pathways and the potential involvement with metabolic disorders. Integrated analysis highlighted enhanced phosphatidylcholine biosynthesis, supported by elevated PCYT1B expression and increased total PC levels in PAS placentas. Lecithin showed higher sensitivity but lower specificity, while PCYT1B displayed intermediate performance. Their combination yielded the best discrimination with an area under the curve (AUC) of 0.791 (95% CI: 0.684-0.899).
conclusionsPAS is characterized by significant alterations in lipid metabolism, particularly increased phosphatidylcholine biosynthesis via the Kennedy pathway. These findings provide new insights into the molecular pathogenesis of PAS and suggest potential metabolic targets for early diagnosis or intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.